Literature DB >> 25631684

Programmable nanomedicine: synergistic and sequential drug delivery systems.

Dennis B Pacardo1, Frances S Ligler, Zhen Gu.   

Abstract

Recent developments in nanomedicine for the cancer therapy have enabled programmable delivery of therapeutics by exploiting the stimuli-responsive properties of nanocarriers. These therapeutic systems were designed with the relevant chemical and physical properties that respond to different triggers for enhanced anticancer efficacy, including the reduced development of drug-resistance, lower therapeutic dose, site-specific transport, and spatiotemporally controlled release. This minireview discusses the current advances in programmable nanocarriers for cancer therapy with particular emphasis on synergistic and sequential drug delivery systems.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25631684     DOI： 10.1039/c4nr07677j

Source DB:  PubMed          Journal:  Nanoscale        ISSN： 2040-3364            Impact factor:   7.790


  32 in total

1.  Sequential delivery of erlotinib and doxorubicin for enhanced triple negative Breast cancer treatment using polymeric nanoparticle.

Authors:  Zilan Zhou; Carly Kennell; Mina Jafari; Joo-Youp Lee; Sasha J Ruiz-Torres; Susan E Waltz; Jing-Huei Lee
Journal:  Int J Pharm       Date:  2017-08-01       Impact factor: 5.875

2.  Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy.

Authors:  Xiaoding Xu; Phei Er Saw; Wei Tao; Yujing Li; Xiaoyuan Ji; Mikyung Yu; Morteza Mahmoudi; Jonathan Rasmussen; Dana Ayyash; Yuxiao Zhou; Omid C Farokhzad; Jinjun Shi
Journal:  Nano Lett       Date:  2017-06-26       Impact factor: 11.189

3.  Metabolite Responsive Nanoparticle-Protein Complex.

Authors:  Krista R Fruehauf; Tae Il Kim; Edward L Nelson; Joseph P Patterson; Szu-Wen Wang; Kenneth J Shea
Journal:  Biomacromolecules       Date:  2019-06-03       Impact factor: 6.988

Review 4.  Programmable biomaterials for dynamic and responsive drug delivery.

Authors:  Anna Stejskalová; Mehrdad T Kiani; Benjamin D Almquist
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-13

Review 5.  Nanoformulations for combination or cascade anticancer therapy.

Authors:  Lei Miao; Shutao Guo; C Michael Lin; Qi Liu; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

Review 6.  Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy.

Authors:  Fanfei Meng; Ning Han; Yoon Yeo
Journal:  Expert Opin Drug Deliv       Date:  2016-08-08       Impact factor: 6.648

Review 7.  Cooperativity Principles in Self-Assembled Nanomedicine.

Authors:  Yang Li; Yiguang Wang; Gang Huang; Jinming Gao
Journal:  Chem Rev       Date:  2018-04-25       Impact factor: 60.622

Review 8.  Manipulating nanoparticle transport within blood flow through external forces: an exemplar of mechanics in nanomedicine.

Authors:  Huilin Ye; Zhiqiang Shen; Le Yu; Mei Wei; Ying Li
Journal:  Proc Math Phys Eng Sci       Date:  2018-03-21       Impact factor: 2.704

Review 9.  Nanomedicines for renal disease: current status and future applications.

Authors:  Nazila Kamaly; John C He; Dennis A Ausiello; Omid C Farokhzad
Journal:  Nat Rev Nephrol       Date:  2016-10-31       Impact factor: 28.314

10.  A dual wavelength-activatable gold nanorod complex for synergistic cancer treatment.

Authors:  Dennis B Pacardo; Bhanu Neupane; S Michaela Rikard; Yue Lu; Ran Mo; Sumeet R Mishra; Joseph B Tracy; Gufeng Wang; Frances S Ligler; Zhen Gu
Journal:  Nanoscale       Date:  2015-06-30       Impact factor: 7.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.